HuL2G7 is a humanized antibody shown to overcome gefitinib resistance in EGFR-mutated human NSCLC cell lines.58 A phase I study conducted in patients with advanced solid malignancies showed that HuL2G7 had no specific dose-limiting toxicities, but adverse events included cough, abdominal pain, constipation and fatigue.59 Further clinical trials have not been pursued. Here, EGFR is linked to non-small cell lung carcinoma.